Tumefactive Multiple Sclerosis Lesions in Two Patients After Cessation of Fingolimod Treatment

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2015 Nov 12

PMID 26557898

Citations 24

Authors

Simon Faissner

Robert Hoepner

Carsten Lukas

Andrew Chan

Ralf Gold

Gisa Ellrichmann

Affiliations

Soon will be listed here.

Abstract

Background: Fingolimod (FTY) is the first oral medication approved for multiple sclerosis therapy. Until now, little has been known about the effects of FTY withdrawal regarding disease activity and development of tumefactive demyelinating lesions (TDLs), as already described in patients who discontinue natalizumab.

Methods: In this study we present the clinical and radiological findings of two patients who had a severe rebound after FTY withdrawal and compare these with patients identified by a PubMed data bank analysis using the search term 'fingolimod rebound'. In total, 10 patients, of whom three developed TDLs, are presented.

Results: Patients suffering from TDLs were free of clinical and radiological signs of disease activity under FTY therapy (100% versus 57%, compared with patients without TDLs) and had rebounds after a mean of 14.6 weeks (standard deviation 11.5) [patients without TDLs 11.7 (standard deviation 3.4)].

Conclusion: We propose that a good therapeutic response to FTY might be predisposing for a severe rebound after withdrawal. Consequently, therapy switches should be planned carefully with a short therapy free interval.

Citing Articles

CNS Resident Innate Immune Cells: Guardians of CNS Homeostasis.

Muzio L, Perego J Int J Mol Sci. 2024; 25(9).

PMID: 38732082 PMC: 11084235. DOI: 10.3390/ijms25094865.

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.

Cerda-Fuertes N, Nagy S, Schaedelin S, Sinnecker T, Ruberte E, Papadopoulou A Ther Adv Neurol Disord. 2023; 16:17562864221150312.

PMID: 36762317 PMC: 9905031. DOI: 10.1177/17562864221150312.

Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.

Faissner S, Gold R CNS Drugs. 2022; 36(8):803-817.

PMID: 35869335 PMC: 9307218. DOI: 10.1007/s40263-022-00939-9.

Multiple Sclerosis Relapses Following Cessation of Fingolimod.

Malpas C, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H Clin Drug Investig. 2022; 42(4):355-364.

PMID: 35303292 PMC: 8989797. DOI: 10.1007/s40261-022-01129-7.

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Schoedel K, Kolly C, Gardin A, Neelakantham S, Shakeri-Nejad K Psychopharmacology (Berl). 2021; 239(1):1-13.

PMID: 34773483 PMC: 8770388. DOI: 10.1007/s00213-021-06011-6.

References

Siffrin V, Muller-Forell W, von Pein H, Zipp F . How to treat tumefactive demyelinating disease?. Mult Scler. 2013; 20(5):631-3. DOI: 10.1177/1352458513516891. View

Dastgir J, DiMario Jr F . Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. J Child Neurol. 2009; 24(4):431-7. DOI: 10.1177/0883073808324769. View

Lucchinetti C, Gavrilova R, Metz I, Parisi J, Scheithauer B, Weigand S . Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008; 131(Pt 7):1759-75. PMC: 2442427. DOI: 10.1093/brain/awn098. View

Calabresi P, Radue E, Goodin D, Jeffery D, Rammohan K, Reder A . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(6):545-56. DOI: 10.1016/S1474-4422(14)70049-3. View

Soelberg Sorensen P, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F . Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014; 261(6):1170-7. DOI: 10.1007/s00415-014-7325-8. View